Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
Lemoine P, et al.
Published in Journal of Sleep Research
Methodology
Randomized, double-blind, placebo-controlled trial of prolonged-release melatonin 2 mg nightly for 3 weeks in primary insomnia patients aged 55+, using the Leeds Sleep Evaluation Questionnaire and withdrawal assessment after cessation.
Key Findings
Prolonged-release melatonin 2 mg for three weeks improved sleep quality and morning alertness versus placebo in insomnia patients aged 55 and older, with no rebound insomnia or withdrawal symptoms after discontinuation.
Conclusions
PR-melatonin is the first drug shown to significantly improve quality of sleep and morning alertness in primary insomnia patients aged 55 years and older-suggesting more restorative sleep, and without withdrawal symptoms upon discontinuation.
Limitations
Short 3-week treatment period, subjective sleep questionnaires without polysomnography for the main outcome, industry sponsorship, and results limited to older adults.
Supplements Studied
PR-melatonin is the first drug shown to significantly improve quality of sleep and morning alertness in primary insomnia patients aged 55 years and older.
Outcomes Measured
Prolonged-release melatonin 2 mg for three weeks improved sleep quality and morning alertness versus placebo in insomnia patients aged 55 and older, with no rebound insomnia or withdrawal symptoms after discontinuation.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.